HERON THERAPEUTICS, INC. /DE/ Insider Trading Activity
Every SEC Form 4 insider transaction reported for HERON THERAPEUTICS, INC. /DE/ (HRTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are HRTX insiders buying or selling?
HERON THERAPEUTICS, INC. /DE/ insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 40 Form 4 filings for HRTX: 13 buys ($20.2M) and 27 sells ($115.8M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Aug 12, 2025)
Total Form 4 filings
40
SEC EDGAR
Insider filers
14
Insider buys (13)
$20.2M
Insider sells (27)
$115.8M
Insider sentiment
Net sellingNet insider flow of $95.6M in net selling since January 2018.
Recent HRTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 12, 2025 | Rubric Capital Management LP | 10% Owner | Purchase | 2.4M | $1.50 | $3.6M | SEC ↗ |
| Aug 12, 2025 | Adam Morgan | Director | Purchase | 1.8M | $1.50 | $2.6M | SEC ↗ |
| Nov 21, 2023 | William P Forbes | EVP, Chief Development Officer | Purchase | 25.0K | $1.09 | $27.3K | SEC ↗ |
| Nov 20, 2023 | William P Forbes | EVP, Chief Development Officer | Purchase | 50.0K | $0.94 | $47.0K | SEC ↗ |
| Nov 17, 2023 | Craig A Collard | Chief Executive Officer | Purchase | 150.0K | $0.92 | $138.0K | SEC ↗ |
| Nov 17, 2023 | Ira Duarte | EVP, Chief Financial Officer | Purchase | 85.0K | $0.89 | $75.6K | SEC ↗ |
| Jul 25, 2023 | Adam Morgan | Director | Purchase | 2.5M | $1.37 | $3.4M | SEC ↗ |
| May 4, 2022 | Kimberly Manhard | EVP, Drug Development | Sale | 1.5K | $4.76 | $7.2K | SEC ↗ |
| Dec 23, 2021 | Waage Christian | Director | Sale | 300 | $9.73 | $2.9K | SEC ↗ |
| Dec 23, 2021 | Craig A Johnson | Director | Sale | 250 | $9.73 | $2.4K | SEC ↗ |
| Sep 23, 2021 | Waage Christian | Director | Sale | 300 | $12.31 | $3.7K | SEC ↗ |
| Sep 23, 2021 | Craig A Johnson | Director | Sale | 250 | $12.30 | $3.1K | SEC ↗ |
| Jun 22, 2021 | Waage Christian | Director | Sale | 300 | $15.20 | $4.6K | SEC ↗ |
| Jun 22, 2021 | Craig A Johnson | Director | Sale | 250 | $15.20 | $3.8K | SEC ↗ |
| May 4, 2021 | Kimberly Manhard | EVP, Drug Development | Sale | 1.5K | $17.66 | $27.0K | SEC ↗ |
| Apr 17, 2021 | Waage Christian | Director | Sale | 300 | $17.51 | $5.3K | SEC ↗ |
| Apr 7, 2021 | Craig A Johnson | Director | Sale | 250 | $17.22 | $4.3K | SEC ↗ |
| Jan 15, 2021 | David Leslie Szekeres | EVP, Chief Operating Officer | Sale | 827 | $18.09 | $15.0K | SEC ↗ |
| Jan 8, 2021 | David Leslie Szekeres | EVP, Chief Operating Officer | Sale | 3.6K | $19.66 | $70.2K | SEC ↗ |
| Dec 23, 2020 | Kimberly Manhard | EVP, Drug Development | Sale | 10.0K | $20.00 | $200.0K | SEC ↗ |
| May 1, 2020 | Kimberly Manhard | Executive VP, Drug Development | Sale | 1.2K | $13.97 | $16.2K | SEC ↗ |
| Dec 3, 2019 | Kimberly Manhard | Executive VP, Drug Development | Sale | 24.0K | $26.00 | $624.0K | SEC ↗ |
| Oct 7, 2019 | TANG KEVIN | Director | Purchase | 285.7K | $17.50 | $5.0M | SEC ↗ |
| Oct 4, 2019 | Barry D Quart | Chief Executive Officer | Purchase | 4.6K | $17.50 | $80.0K | SEC ↗ |
| Oct 4, 2019 | John Poyhonen | EVP, Chief Commercial Officer | Purchase | 5.1K | $17.50 | $90.0K | SEC ↗ |
Showing the 25 most recent of 40 Form 4 filings for HERON THERAPEUTICS, INC. /DE/.
Most active HRTX insiders
- Kimberly Manhard11 filings
- Waage Christian5 filings
- Barry D Quart4 filings
- Craig A Johnson4 filings
- TANG KEVIN C3 filings
Ask anything about HRTX insider activity
Use Trabud's AI agent to query HERON THERAPEUTICS, INC. /DE/'s Form 4 history in plain English — "Show me HRTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentHRTX insider trading FAQ
Are HERON THERAPEUTICS, INC. /DE/ insiders buying or selling?
HERON THERAPEUTICS, INC. /DE/ insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 40 Form 4 filings for HRTX: 13 buys ($20.2M) and 27 sells ($115.8M). Over the full record that is net selling of $95.6M.
How many insiders trade HRTX stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for HERON THERAPEUTICS, INC. /DE/. The most recent filing was accepted on Aug 12, 2025.
Where does Trabud get HRTX insider trading data?
All HRTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.